New Insight: Phase 2 BEHOLD Study and UBX1325 for DME, Live at AAO 2023

News
Article

On the floor at AAO 2023, host Veeral Sheth, MD, discusses UBX1325 for patients with diabetic macular edema, based on the 48-week results from the phase 2 BEHOLD study.

Episode Highlights

0:30 Introduction
0:48 Background into UBX1325 and BEHOLD
2:49 BEHOLD 48-week results
6:05 Next steps
6:56 Conclusion

On the floor at AAO 2023, host Veeral Sheth, MD, and producer Connor Iapoce discuss UBX1325 for patients with diabetic macular edema (DME), based on the 48-week results from the phase 2 BEHOLD study.

Every episode of New Insight is available on HCPLive.com and be sure to subscribe to our channel on Spotify, Apple Podcasts, and YouTube. Please direct any podcast-related inquiries to show producer Connor Iapoce at ciapoce@mjhlifesciences.com.

Keep an eye out for more from New Insight!

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Brendon Neuen, MBBS, PhD | Credit: X.com
4 KOLs are featured in this series
4 KOLs are featured in this series
M. Safwan Badr, MD: Novel Treatments for Central Sleep Apnea in Last 10 Years
Video 4 - Featuring 3 KOLs in, "Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease "
Video 3 - Featuring 3 KOLs in, "How important is transmural healing as a treatment target in UC and CD?   Where does intestinal ultrasound fit in CD management?  "
How Elite Athletes Can Optimize Sleep for Peak Performance, with Jesse D. Cook, PhD
© 2024 MJH Life Sciences

All rights reserved.